Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)
- 171 Downloads
Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC).
A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated.
Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04).
SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.
KeywordsCachexia Chemotherapy response Metastatic colorectal cancer Sarcopenia Skeletal muscle loss
This study received no financial or material support. The authors thank the following institutions and investigators who participated in this study: Baba H (Kumamoto University Hospital), Kakeji Y (Kobe University Hospital), Akagi Y (Kurume University Hospital), Ogata Y (Kurume University Hospital), Eguchi S (Nagasaki University Hospital), Nishimaki T (Ryukyu University Hospital), and Natsugoe S (Kagoshima University Hospital). We also thank Sakamoto S and the staff at the Clinical Research Support Center Kyushu (CReS Kyushu) for their excellent data collection and management and secretarial assistance. We thank Shimose T for the statistical analysis. This work was supported by CReS Kyushu with no funding. We would like to thank Editage (https://www.editage.jp) for English language editing.
Compliance with ethical standards
Conflict of interest
We declare that we have no conflict of interest.
- 18.Miwa K, Oki E, Emi Y et al (2016) Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). Int J Clin Oncol 21:110–117. https://doi.org/10.1007/s10147-015-0850-3 CrossRefGoogle Scholar
- 19.Beppu T, Emi Y, Tokunaga S et al (2014) Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study). Anticancer Res 34:6655–6662Google Scholar
- 21.Oki E, Emi Y, Miyamoto Y et al (2015) Phase II trial of S-1 and oxaliplatin plus cetuximab for colorectal cancer patients with initially unresectable or not optimally resectable liver metastases (KSCC1002). Ann Surg Oncol 22(Suppl 3):S1067–S1074. https://doi.org/10.1245/s10434-015-4771-1 CrossRefGoogle Scholar
- 27.Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635. https://doi.org/10.1016/S1470-2045(08)70153-0 CrossRefGoogle Scholar
- 44.Fukushima H, Kataoka M, Nakanishi Y et al (2018) Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Urol Oncol 36:156.e9–156.e16. https://doi.org/10.1016/j.urolonc.2017.09.016 CrossRefGoogle Scholar